Clinical trials: Mild Alzheimer Disease
Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
Digital Solutions for Predicting the Biological Mechanisms of Alzheimer's Disease Through the Analysis of Risk Factors
Population ageing is one of the main factors responsible for the global increase in the prevalence of dementia. Recent evidence suggests that modifiable risk factors, such as cardiovascular disease and lifestyle, may increase the…
- Trial name
- PrevAl (NCT07731191)
- Testing
- Digital solution for the prediction of the biological mechanisms of Alzheimer's disease through the analysis of risk factors
- Where
- 2 sites in Italy
- Volunteers
- 240 people
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Mild Cognitive Impairment, Probable Alzheimer's Disease
Dietary Treatments for Cognitive Impairment in Older Adults
This trial seeks to establish the feasibility of implementing a ketogenic, modified Atkins diet (MAD) to older adults with mild cognitive impairment (MCI) or early Alzheimer's disease (AD) living in the community.
- Trial name
- NCT02521818
- Testing
- Modified Atkins Diet, NIA Diet for Seniors
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Johns Hopkins University
Alzheimer's Disease
A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia
The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia.
- Trial name
- NAVIGATE-AD (NCT02791191)
- Testing
- LY3202626
- Where
- 76 sites in United States, Australia and 2 more
- Volunteers
- 316 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, Dementia
Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial
The main purpose of this study is to build upon the evidence captured in the Imaging Dementia - Evidence for Amyloid Scanning (IDEAS; NCT02420756) trial to include valuable information regarding patient-reported outcomes and…
- Conditions
- Mild Cognitive Impairment, Dementia, Alzheimer's Disease
- Trial name
- IMPACT2 (NCT02781220)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Utah
Mild Cognitive Impairment, Alzheimer Disease
Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Alzheimer's disease (AD) is the most common type of dementia, accounting for 50-75% of the estimated 47 million people with dementia worldwide.
- Trial name
- NCT03461276
- Testing
- ABvac40
- Where
- 23 sites in France, Italy and 2 more
- Volunteers
- 134 people
- Sponsor
- Araclon Biotech S.L.
Mild Cognitive Impairment, Dementia
Implications for Management of PET Amyloid Classification Technology
The main purpose of this study is to explore the impact of an amyloid positron emission tomography and computed tomography (PET/CT) scan on physician diagnosis and management, including drug management and care practices, for…
- Conditions
- Mild Cognitive Impairment, Dementia, Alzheimer's Disease
- Trial name
- IMPACT (NCT02778971)
- Testing
- [18F]Flutemetamol
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Utah
MCI, MCI Conversion to Dementia
Neurocognitive Assessment Platform 4 Alzheimer
The aging population in Europe is leading to an increase in neurodegenerative diseases, such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050.
- Conditions
- MCI, MCI Conversion to Dementia, AMCI - Amnestic Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NAP4A2020 (NCT07272811)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Mild Cognitive Impairment
DIGITAL Biomarker: Blood Based Biomarkers in the Primary Care Setting for Alzheimer's Disease
The primary objective of this study is to evaluate the feasibility of implementing blood-based biomarker testing for amyloid positivity designed to aid the early detection of Alzheimer's Disease and Related Dementia (ADRD) in…
- Trial name
- DIGITAL (NCT05844488)
- Testing
- PrecivityAD
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Indiana University
Mild Alzheimer's Disease
Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients
Eligible patients will undergo this open label initial safety and feasibility study investigating the use of 6 g/day sodium oxybate in mild AD.
- Trial name
- ALD (NCT00706186)
- Testing
- Sodium Oxybate
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Clayton Sleep Insititute
Mild Cognitive Impairment, Alzheimer Disease
Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2
To test the long term effect of a light treatment on cognition, sleep and metabolism in patients with Mild cognitive impairment (MCI) or mild Alzheimer's disease or related dementia (ADRD).
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Type2 Diabetes
- Trial name
- NCT03933696
- Testing
- Tailored Lighting Intervention
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI)
Positive Psychology for Early Cognitive Decline: Effects on Cognitive and Brain Function
This randomized study tests whether a new multicomponent Positive Psychology program can improve cognition and wellbeing in older adults at the earliest stages of dementia-related decline.
- Conditions
- Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD)
- Trial name
- NCT07289061
- Testing
- Positive Psychology Intervention, Treatment as usual (TAU)
- Where
- Greece
- Volunteers
- 128 people
- Sponsor
- Aristotle University Of Thessaloniki
Alzheimer Disease, Cognitive Impairment
Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease
The primary purpose of this study is to determine whether sodium oligo-mannurarate capsule is effective and safe in the treatment of mild to moderate alzheimer' disease, and to determine the best therapeutic dose of sodium…
- Trial name
- NCT01453569
- Testing
- Sodium oligo-mannurarate 600mg, Sodium oligo-mannurarate 900mg
- Where
- 24 sites in China
- Volunteers
- 255 people
- Sponsor
- Shanghai Greenvalley Pharmaceutical Co., Ltd.
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease, Mild Cognitive Impairment
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline
- Trial name
- QUIP II (NCT06025877)
- Testing
- PrecivityAD2(TM) blood test
- Where
- 9 sites in United States
- Volunteers
- 400 people
- Sponsor
- C2N Diagnostics
Cognition Disorder, Nervous System Diseases
A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
The purpose of this follow-up study is to assess the long-term safety and tolerability of galantamine in individuals with mild cognitive impairment who participated in a previous study with galantamine
- Conditions
- Cognition Disorder, Nervous System Diseases, Mental Disorders, Brain Diseases
- Trial name
- NCT00240695
- Testing
- galantamine hydrobromide
- Volunteers
- 724 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD.
- Trial name
- NCT03443973
- Testing
- Gantenerumab
- Where
- 155 sites in United States, Argentina and 17 more
- Volunteers
- 975 people
- Sponsor
- Hoffmann-La Roche
Mild Cognitive Impairment (MCI)
Working Memory Training in Patients with Mild Cognitive Impairment
The purpose of this study is to test whether a special memory training program, called CogMed, can help people with early memory problems.
- Trial name
- NCT06734286
- Testing
- CogMed
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Alzheimer Disease
Efficacy and Safety of NVP-NK4146 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
The purpose of this clinical trial is to exploratively evaluate the efficacy and safety of NVP -NK4146 in improving mild cognitive impairment (MCI) in patients with due to Alzheimer's disease (AD) compared to placebo
- Trial name
- NCT06761066
- Testing
- NVP-NK4146
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- NVP Healthcare
Alzheimer's Disease
Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil
To establish efficacy of Idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).
- Trial name
- STARBEAM (NCT02006641)
- Testing
- Idalopirdine
- Where
- 162 sites in United States, Argentina and 17 more
- Volunteers
- 858 people
- Sponsor
- H. Lundbeck A/S
Subjective Cognitive Decline, Alzheimer Disease
Using Artificial Intelligence to Detect Early Signs of Alzheimer's Disease in People With Memory Concerns
AHEAD is a prospective, longitudinal, risk-stratified single-arm interventional study enrolling 300 patients with Subjective Cognitive Decline (SCD) at IRCCS San Raffaele Hospital, Milan, Italy.
- Conditions
- Subjective Cognitive Decline, Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- AHEAD (NCT07652931)
- Testing
- High-frequency Transcranial Magnetic Stimulation (TMS), Digital Cognitive Training, Structured Physical Exercise
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS San Raffaele